Optimising detection and stroke prevention strategies in patients with Atrial Fibrillation in West Hampshire
|
|
- Arnold Davidson
- 5 years ago
- Views:
Transcription
1 Optimising detection and stroke prevention strategies in patients with Atrial Fibrillation in West Hampshire Dr Chris Arden GP, Chandlers Ford GPSI Cardiology, Southampton West Hampshire CCG Cardiovascular Lead Friday 10 th November 2017 Nottingham
2 Projected Number of Patients With AF by 2050 MarketScan & Thomson Reuters Medicare databases, 2009 Olmsted County data, 2006 (assuming a continued increase in the AF incidence) Olmsted County data, 2006 (assuming no further increase in the AF incidence) ATRIA study data,
3 ANTICOAGULATION
4 How do we screen for AF?
5 Preventing stroke in West Hampshire We want to: improve the identification of asymptomatic/undiagnosed AF in WHCCG (an estimated 2000 patients) via opportunistic screening utilising the NICE endorsed WatchBP monitor; saving target - 30 strokes per year at a cost of 126k with zero investment.
6 West Hampshire CCG 546,000 population 106,000 over 65s 16,000 over 85s 119,000 under 20 Ageing population 51 practices 2,000 undiagnosed AF 12,000 people with AF 10,500 AF high risk stroke
7 National drivers
8 Preventing stroke in West Hampshire Strategy A collaborative plan involving WHCCG Long Term Conditions/GPs/Medicines management and pharma STEP 1 PROACTIVE LEADERSHIP Awareness raising/public Health Audit 2012 Multi-level educational sessions/events Use of incentives/levers QOF/LES/QIPP Analysis/needs-gap evaluation/business case STEP 2 OPPORTUNISTIC SCREENING Screening programme targeting high risk asymptomatic patients Introduction of NICE endorsed WatchBPTool Early adopter 3B Practices/wider roll-out WHCCG Reinforce educational sessions STEP 3 OPTIMISING ANTICOAGULATION AND REPORTING Medicines Management LES Quality/Safety Intervention Anticoagulation education NOACS v Warfarin Improving uptake of GRASP AF Tool + WPSAT/CHADS2VASC Uploading to National dataset Community Pharmacy Interventions NICE KPIs STEP 4 EVALUATION/AUDIT Record monitor progress improvements via GRASP AF Increased NOAC prescribing audit Introduction of AF/anticoagulation nurse? Public Health Audit/participation in National trials Oxford + Southampton Review of anticoagulation provision/increasing INR self- testing opportunities/primary care community delivered cardiology services
9 Optimising Care: The Plan Identify undiagnosed AF using WatchBP tool Identify and treat people not treated with OAC Identify people on warfarin sub-optimally-controlled
10 Atrial fibrillation screening
11 Evaluation of WatchBP devices in the diagnosis of Atrial Fibrillation in a Primary Care setting Honney R 1,2, Su F 1, Arden C 3, Pears R 2 & Roderick P 1 Background: Atrial fibrillation (AF) is a leading cause of preventable stroke but 20% of patients remain undiagnosed 1. Modified blood pressure devices, such as Microlife s WatchBP, have been shown to be more sensitive and specific than manual pulse palpation when used to opportunistically screen for AF 2. There is limited literature on the clinical impact of introducing such devices into UK general practice. Although stroke reduction is a primary aim of the Health Check process, assessment of pulse rhythm is not explicitly stated in the Health Check protocol. Methods: This natural experiment used routinely collected GP data from the Hampshire Health Record (HHR) covering 146 practices (1,146,163 people), to evaluate the clinical utility of introducing WatchBP devices to chronic disease clinics in 44 practices in West Hampshire Clinical Commissioning Group (WHCCG). The remaining 102 practices were controls. Practice rates of incident AF were compared two months after introducing WatchBP, and Negative Binomial Regression was used to adjust for practice level confounders. An internationally recognised stroke risk assessment tool, CHA2DS2-VASc, was used to assess for changes in newly diagnosed AF severity. Results: The introduction of WatchBP devices was associated with an adjusted 26% relative increase in AF detection rate compared to current best practice (Incident Rate Ratio=1.26, 95% CI= ). The rate of high risk AF diagnoses also increased (IRR=1.25, 95% CI= ). significantly different between WHCCG (72.21%) and control (71.57%) practices (χ 2 =0.0456, p=0.831). The mean absolute increase rate of AF detection observed in the intervention practices was 0.4 cases per 1000 person years, which extrapolated throughout WHCCG would be 188 additional AF diagnoses annually. The proportion of newly diagnosed high risk patients receiving anticoagulation was not Conclusions: Given the observational nature of the study design and with limited follow up time and a lack of data on device usage, these results should be interpreted as preliminary. However, the study does suggest that WatchBP may increase rates of AF diagnosis in primary care, ultimately contributing to stroke risk reduction. Using WatchBP to measure blood pressure as part of a Health Check may increase the clinical impact of the programme. References: 1 The National Cardiovascular Intelligence Network. The National Cardiovascular Intelligence Network Cardiovascular disease key facts Atrial fibrillation.public Health England; Wiesel J, et al., Comparison of the Microlife blood pressure monitor with the Omron blood pressure monitor for detecting atrial fibrillation. Am J Cardiol 2014;114(7): University of Southampton, Southampton. UK. 2 Hampshire County Council, Winchester. UK. 3 West Hampshire Clinical Commissioning Group, Eastleigh. UK. Contact: r.honney@nhs.net
12 Evaluation of WatchBP devices in the diagnosis of Atrial Fibrillation in a Primary Care setting Honney R 1,2, Su F 1, Arden C 3, Pears R 2 & Roderick P 1 Background: Atrial fibrillation (AF) is a leading cause of preventable stroke but 20% of patients remain undiagnosed 1. Modified blood pressure devices, such as Microlife s WatchBP, have been shown to be more sensitive and specific than manual pulse palpation when used to opportunistically screen for AF 2. There is limited literature on the clinical impact of introducing such devices into UK general practice. Although stroke reduction is a primary aim of the Health Check process, assessment of pulse rhythm is not explicitly stated in the Health Check protocol. Methods: This natural experiment used routinely collected GP data from the Hampshire Health Record (HHR) covering 146 practices (1,146,163 people), to evaluate the clinical utility of introducing WatchBP devices to chronic disease clinics in 44 practices in West Hampshire Clinical Commissioning Group (WHCCG). The remaining 102 practices were controls. Practice rates of incident AF were compared two months after introducing WatchBP, and Negative Binomial Regression was used to adjust for practice level confounders. An internationally recognised stroke risk assessment tool, CHA2DS2-VASc, was used to assess for changes in newly diagnosed AF severity. Results: The introduction of WatchBP devices was associated with an adjusted 26% relative increase in AF detection rate compared to current best practice (Incident Rate Ratio=1.26, 95% CI= ). The rate of high risk AF diagnoses also increased (IRR=1.25, 95% CI= ). significantly different between WHCCG (72.21%) and control (71.57%) practices (χ 2 =0.0456, p=0.831). The mean absolute increase rate of AF detection observed in the intervention practices was 0.4 cases per 1000 person years, which extrapolated throughout WHCCG would be 188 additional AF diagnoses annually. The proportion of newly diagnosed high risk patients receiving anticoagulation was not Conclusions: Given the observational nature of the study design and with limited follow up time and a lack of data on device usage, these results should be interpreted as preliminary. However, the study does suggest that WatchBP may increase rates of AF diagnosis in primary care, ultimately contributing to stroke risk reduction. Using WatchBP to measure blood pressure as part of a Health Check may increase the clinical impact of the programme. References: 1 The National Cardiovascular Intelligence Network. The National Cardiovascular Intelligence Network Cardiovascular disease key facts Atrial fibrillation.public Health England; Wiesel J, et al., Comparison of the Microlife blood pressure monitor with the Omron blood pressure monitor for detecting atrial fibrillation. Am J Cardiol 2014;114(7): University of Southampton, Southampton. UK. 2 Hampshire County Council, Winchester. UK. 3 West Hampshire Clinical Commissioning Group, Eastleigh. UK. Contact: r.honney@nhs.net
13 Evaluation of WatchBP devices in the diagnosis of Atrial Fibrillation in a Primary Care setting Honney R 1,2, Su F 1, Arden C 3, Pears R 2 & Roderick P 1 Background: Atrial fibrillation (AF) is a leading cause of preventable stroke but 20% of patients remain undiagnosed 1. Modified blood pressure devices, such as Microlife s WatchBP, have been shown to be more sensitive and specific than manual pulse palpation when used to opportunistically screen for AF 2. There is limited literature on the clinical impact of introducing such devices into UK general practice. Although stroke reduction is a primary aim of the Health Check process, assessment of pulse rhythm is not explicitly stated in the Health Check protocol. Methods: This natural experiment used routinely collected GP data from the Hampshire Health Record (HHR) covering 146 practices (1,146,163 people), to evaluate the clinical utility of introducing WatchBP devices to chronic disease clinics in 44 practices in West Hampshire Clinical Commissioning Group (WHCCG). The remaining 102 practices were controls. Practice rates of incident AF were compared two months after introducing WatchBP, and Negative Binomial Regression was used to adjust for practice level confounders. An internationally recognised stroke risk assessment tool, CHA2DS2-VASc, was used to assess for changes in newly diagnosed AF severity. Results: The introduction of WatchBP devices was associated with an adjusted 26% relative increase in AF detection rate compared to current best practice (Incident Rate Ratio=1.26, 95% CI= ). The rate of high risk AF diagnoses also increased (IRR=1.25, 95% CI= ). significantly different between WHCCG (72.21%) and control (71.57%) practices (χ 2 =0.0456, p=0.831). The mean absolute increase rate of AF detection observed in the intervention practices was 0.4 cases per 1000 person years, which extrapolated throughout WHCCG would be 188 additional AF diagnoses annually. The proportion of newly diagnosed high risk patients receiving anticoagulation was not Conclusions: Given the observational nature of the study design and with limited follow up time and a lack of data on device usage, these results should be interpreted as preliminary. However, the study does suggest that WatchBP may increase rates of AF diagnosis in primary care, ultimately contributing to stroke risk reduction. Using WatchBP to measure blood pressure as part of a Health Check may increase the clinical impact of the programme. References: 1 The National Cardiovascular Intelligence Network. The National Cardiovascular Intelligence Network Cardiovascular disease key facts Atrial fibrillation.public Health England; Wiesel J, et al., Comparison of the Microlife blood pressure monitor with the Omron blood pressure monitor for detecting atrial fibrillation. Am J Cardiol 2014;114(7): University of Southampton, Southampton. UK. 2 Hampshire County Council, Winchester. UK. 3 West Hampshire Clinical Commissioning Group, Eastleigh. UK. Contact: r.honney@nhs.net
14 Evaluation of WatchBP devices in the diagnosis of Atrial Fibrillation in a Primary Care setting Honney R 1,2, Su F 1, Arden C 3, Pears R 2 & Roderick P 1 Background: Atrial fibrillation (AF) is a leading cause of preventable stroke but 20% of patients remain undiagnosed 1. Modified blood pressure devices, such as Microlife s WatchBP, have been shown to be more sensitive and specific than manual pulse palpation when used to opportunistically screen for AF 2. There is limited literature on the clinical impact of introducing such devices into UK general practice. Although stroke reduction is a primary aim of the Health Check process, assessment of pulse rhythm is not explicitly stated in the Health Check protocol. Methods: This natural experiment used routinely collected GP data from the Hampshire Health Record (HHR) covering 146 practices (1,146,163 people), to evaluate the clinical utility of introducing WatchBP devices to chronic disease clinics in 44 practices in West Hampshire Clinical Commissioning Group (WHCCG). The remaining 102 practices were controls. Practice rates of incident AF were compared two months after introducing WatchBP, and Negative Binomial Regression was used to adjust for practice level confounders. An internationally recognised stroke risk assessment tool, CHA2DS2-VASc, was used to assess for changes in newly diagnosed AF severity. Results: The introduction of WatchBP devices was associated with an adjusted 26% relative increase in AF detection rate compared to current best practice (Incident Rate Ratio=1.26, 95% CI= ). The rate of high risk AF diagnoses also increased (IRR=1.25, 95% CI= ). significantly different between WHCCG (72.21%) and control (71.57%) practices (χ 2 =0.0456, p=0.831). The mean absolute increase rate of AF detection observed in the intervention practices was 0.4 cases per 1000 person years, which extrapolated throughout WHCCG would be 188 additional AF diagnoses annually. The proportion of newly diagnosed high risk patients receiving anticoagulation was not Conclusions: Given the observational nature of the study design and with limited follow up time and a lack of data on device usage, these results should be interpreted as preliminary. However, the study does suggest that WatchBP may increase rates of AF diagnosis in primary care, ultimately contributing to stroke risk reduction. Using WatchBP to measure blood pressure as part of a Health Check may increase the clinical impact of the programme. References: 1 The National Cardiovascular Intelligence Network. The National Cardiovascular Intelligence Network Cardiovascular disease key facts Atrial fibrillation.public Health England; Wiesel J, et al., Comparison of the Microlife blood pressure monitor with the Omron blood pressure monitor for detecting atrial fibrillation. Am J Cardiol 2014;114(7): University of Southampton, Southampton. UK. 2 Hampshire County Council, Winchester. UK. 3 West Hampshire Clinical Commissioning Group, Eastleigh. UK. Contact: r.honney@nhs.net
15 Evaluation of WatchBP devices in the diagnosis of Atrial Fibrillation in a Primary Care setting Honney R 1,2, Su F 1, Arden C 3, Pears R 2 & Roderick P 1 References: 1 The National Cardiovascular Intelligence Network. The National Cardiovascular Intelligence Network Cardiovascular disease key facts Atrial fibrillation.public Health England; Wiesel J, et al., Comparison of the Microlife blood pressure monitor with the Omron blood pressure monitor for detecting atrial fibrillation. Am J Cardiol 2014;114(7): University of Southampton, Southampton. UK. 2 Hampshire County Council, Winchester. UK. 3 West Hampshire Clinical Commissioning Group, Eastleigh. UK. Contact: r.honney@nhs.net
16 Optimising Care: The Method Audit tools identified patients at high risk of stroke Results to GPs & continuous feedback on improvement Education and training was delivered Medicines Optimisation Incentive Scheme identification, feedback, education = continuous health improvement
17 GRASP AF An automated tool to identify patients at high risk of stroke in AF and not on adequate thromboprophylaxis, using existing GP data Delivered by PRIMIS+ and available via your Cardiac Network.
18 Audit of Atrial Fibrillation & CHADS2-VASc Scores Classic View Select Risk Score Practice: CHADS2-VASc CHA2DS2-VASc Total Practice Population Total Percent No. with Atrial Fibrillation Age >= 65 yrs with AF NB: Handling of anticoagulant exclusions Age range AF prevalence (%) by age band AF prevalence (%) Percentage Risk profile for thrombo-embolism 0 1 >1 CHA2DS2-VASc score HF or LVD Hypertension Age >=75 Diabetes Stroke or TIA Vasc disease Age Risk factors in patients with AF CHA2DS2-VASc score Breakdown of anticoagulant & antiplatelet use by CHA2DS2-VASc score > Anticoagulant Both Antiplatelet None Sex = Female 0% 20% 40% 60% 80% 100% 0% 20% 40% 60% 80% Percentage Percentage Anticoagulant use in high risk patients On anticoagulant (121 patients) Not on anticoagulant (73 patients) Strokes expected annually in the 73 high risk untreated 2.9 Percentage Score or review in last 15 mths CHADS2 AF review HELP OVERVIEW PODCAST PRIMIS+ 2011
19 Optimising Care: GRASP AF Total number of expected strokes annually Sep Mar Sept Sep Mar Sept Sep Mar Sept
20 Optimising Care: WPSAT Apr % Mar % Sept % Apr 15 59% Mar 16 67% Sept 16 67%
21 Optimising Care: The Results WPSAT 3000 people poorly-controlled on warfarin reviewed
22 Optimising Care: The Results WatchBP GRASP AF Before No OAC On OAC 2071 more OAC 39 expected strokes avoided
23 Number of reported strokes across WHCCG
24 Optimising Care: What next? WatchBP to AliveCor Review 1500 high-risk patients receiving antiplatelet monotherapy Review 1500 high-risk patients not receiving OAC or those poorly-controlled on warfarin Getting improvement work embedded into routine clinical practice (including care home residents)
Optimising detection and stroke prevention strategies in patients with Atrial Fibrillation in West Hampshire
Optimising detection and stroke prevention strategies in patients with Atrial Fibrillation in West Hampshire Dr Chris Arden GP, Chandlers Ford GPSI Cardiology, Southampton West Hampshire CCG Cardiovascular
More informationTackling atrial fibrillation the health economics evidence
Tackling atrial fibrillation the health economics evidence Professor Gary Ford,CBE Chief Executive Officer, Oxford Academic Health Science Network Consultant Stroke Physician, Oxford University Hospitals
More informationMedicines Optimisation Annual Report Dr Emma Harris and Neil Hardy on behalf of the Medicines Management Team June 2016
Medicines Optimisation Annual Report 2015-2016 Dr Emma Harris and Neil Hardy on behalf of the Medicines Management Team June 2016 1 Clinical Objectives Improve the effective use of medicines Maximise health
More informationQuestion 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:
Atrial Fibrillation in Your Area Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: a) What was the prevalence of atrial fibrillation (AF)? 6636 (as of 22/10/2015) 2.1%
More informationrequesting information regarding atrial fibrillation in NHS Ashford Clinical Commissioning Group
October 2015 Our Ref: FOI.15.ASH0149 requesting information regarding atrial fibrillation in NHS Ashford Clinical Commissioning Group Original Request Survey attached. Question 1: Between 1 July 2014 and
More informationGetting Serious About CVD Prevention What does this mean for Primary Care?
Getting Serious About CVD Prevention What does this mean for Primary Care? Dr Matt Kearney GP and National Clinical Director for Cardiovascular Disease Prevention NHS England and Public Health England
More informationGRASP-AF- The National Picture. Dr Richard Healicon National Improvement Lead Ian Robson Senior Analyst NHS Improvement February 2012
GRASP-AF- The National Picture Dr Richard Healicon National Improvement Lead Ian Robson Senior Analyst NHS Improvement February 2012 Outline AF and stroke Objective Management of stroke risk Stroke risk
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence
More informationAtrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
More informationAtrial fibrillation detection and management. Professor Lis Neubeck Head of Theme Long Term Conditions
Atrial fibrillation detection and management Professor Lis Neubeck Head of Theme Long Term Conditions Atrial fibrillation Most common cardiac arrhythmia Symptoms range from severely debilitating to none
More informationAHSN Business Case User Guide: Improving AF Identification and Optimising Management to Prevent AF-Related Stroke. Version: 13 March 2017
AHSN Business Case User Guide: Improving AF Identification and Optimising Management to Prevent AF-Related Stroke Version: 13 March 2017 Introduction This business case template has been created so that
More informationThe Size of the Prize Doing Things Differently To Prevent Heart Attacks and Strokes at Scale
The Size of the Prize Doing Things Differently To Prevent Heart Attacks and Strokes at Scale Dr Matt Kearney GP and National Clinical Director for Cardiovascular Disease Prevention NHS England and Public
More informationReview of devices for early AF detection Nadya Hamedi Primary Care cardiovascular pharmacist Health innovation Network
Review of devices for early AF detection Nadya Hamedi Primary Care cardiovascular pharmacist Health innovation Network n.hamedi@nhs.net HRC 2016 The ICC Birmingham UK 9-12 October 2016 PAN London AF Improvement
More informationThat the Single Commissioning Board supports the project outlined in this report and proceeds as described.
Report to: SINGLE COMMISSIONING BOARD Date: 26 September 2017 Officer of Single Commissioning Board Subject: Report Summary: Recommendations: Jessica Williams Interim Director of Commissioning ATRIAL FIBRILLATION
More informationADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE
ADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE HELEN WILLIAMS FFRPS, MRPHARMS, PGDIP (CARDIOL) IPRESC CONSULTANT PHARMACIST FOR CVD, SOUTH LONDON CLINICAL LEAD FOR ATRIAL FIBRILLATION, HEALTH INNOVATION
More informationCommissioning for value focus pack
Commissioning for value focus pack Clinical commissioning group: NHS MILTON KEYNES CCG Focus area: Cardiovascular disease (CVD) pathway Version 2 June 2014 Contents 1. Background and context About the
More informationCosting Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180)
Putting NICE guidance into practice Costing Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180) Published: June 2014 This costing report accompanies the clinical
More informationCVD Prevention Optimal Value Pathway
CVD Prevention Optimal Value Pathway Miles Freeman NHS RightCare Dr Matt Kearney GP and National Clinical Director CVD Prevention 22 nd November 2016 Structure Rightcare Background Why OVP? Key elements
More informationHypertension How can we do better at preventing strokes and heart attacks?
Hypertension How can we do better at preventing strokes and heart attacks? Dr Matt Kearney GP and National Clinical Director for Cardiovascular Disease Prevention NHS England and Public Health England
More informationQuality Improvement Tool Instruction Guide GRASP-AF
Quality Improvement Tool Instruction Guide GRASP-AF The GRASP-AF quality improvement tool has been developed by PRIMIS and delivered in partnership with NHS England. Prepared by PRIMIS September 2017 The
More informationGOVERNING BODY REPORT
GOVERNING BODY REPORT DATE OF MEETING: 20th September 2012 TITLE OF REPORT: KEY MESSAGES: NHS West Cheshire Clinical Commissioning Group has identified heart disease as one of its six strategic clinical
More informationAF Stroke Prevention Through Screening, Intervention and Patient Choice
AF Stroke Prevention Through Screening, Intervention and Patient Choice Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GP Partner Westcliffe Medical Group Trustee AF Association Trustee
More informationAF detection: What s new? Christopher B. Granger
AF detection: What s new? Christopher B. Granger Disclosures Research contracts: Apple, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Novartis, GSK, Medtronic Foundation, Pfizer,
More informationAgenda Item No. 8a SERVICE SPECIFICATION. 1. Introduction:
SERVICE SPECIFICATION Agenda Item No. 8a Service Specification No. Service Atrial Fibrillation Audit patient reviews Commissioner Lead Caroline Davidson Period 1 st September to 31 st March 2017 Date of
More informationThe case against structured screening for Atrial Fibrillation in General Practice
The case against structured screening for Atrial Fibrillation in General Practice THE CASE AGAINST STRUCTURED SCREENING FOR ATRIAL FIBRILLATION IN GENERAL PRACTICE or the PCCJ conference Nov 2015 r Ivan
More informationManuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
More informationNHS England Getting Serious About Prevention
NHS England Getting Serious About Prevention Dr Matt Kearney GP and National Clinical Director for Cardiovascular Disease Prevention NHS England and Public Health England The NHS needs a radical upgrade
More informationAtrial Fibrillation Key Messages
Atrial Fibrillation Key Messages Dr Matthew Fay Westcliffe Medical Practice National Clinical Lead NHS Improvement www.escardio.org/guidelines European Heart Journal (2010) 31, 2369-2429 Clinical Events
More informationConsensus document: Screening and Prevention of Atrial Fibrillation
Consensus document: Screening and Prevention of Atrial Fibrillation Yong-Seog Oh, M.D.,Ph.D. Division of Cardiology, Department of Internal Medicine, Seoul St. Mary s Hospital, College of Medicine, The
More informationProfessor DA Fitzmaurice Primary Care Clinical Sciences University of Birmingham
New Guidelines for SPAF Professor DA Fitzmaurice Primary Care Clinical Sciences University of Birmingham Stroke prevention and atrial fibrillation Epidemiology of atrial fibrillation How common is it?
More informationCase Study. A Campaign to Raise Awareness of Atrial Fibrillation (AF) in Lancashire. June 2015.
Case Study A Campaign to Raise Awareness of Atrial Fibrillation (AF) in Lancashire. June 2015. North West Coast Academic Health Science Network AF/Stroke Prevention Programme Academic Health Science Networks
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationAudit+ Atrial Fibrillation Module (beta V2.1) quick start guide To Review Therapy
Save A Stroke Campaign 2016 Quality Improvement Cardiff & Vale UHB & Public Health Wales Audit+ Atrial Fibrillation Module (beta V2.1) quick start guide To Review Therapy 1 Quality Improvement [AUDIT+
More informationNHS Rotherham Clinical Commissioning Group
NHS Rotherham Clinical Commissioning Group Operational Executive: 2 nd November 2015 Governing Body: 4 th November 2015 Review of Stroke Care Pathway GP Lead: Dr Phil Birks Lead Executive: Keely Firth
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationDefining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
More informationAtrial Fibrillation. A guide for Southwark General Practice. Key Messages. Always work within your knowledge and competency
Atrial Fibrillation A guide for Southwark General Practice Key Messages 1. Routinely offer pulse checks to patients at high risk of AF 2. Use the CHA 2 DS 2 VASc score to identify patients for anticoagulation
More informationEconomic Impact Evaluation Case Study: AliveCor Kardia Mobile
NHS Innovation Accelerator Economic Impact Evaluation Case Study: AliveCor Kardia Mobile 1. BACKGROUND The AliveCor Kardia Mobile ECG (Kardia Mobile) is a portable single-channel cardiac event recorder
More informationTrends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation,
Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017 Junya Zhu, PhD Department of Health Policy and Management January 23, 2018 Acknowledgments Co-Authors G.
More informationManagement of Atrial Fibrillation in Primary Care
Cardiac and Stroke Networks in Lancashire & Cumbria Lancaster Morecambe Carnforth and Garstang PBC North Lancashire Teaching PCT Management of Atrial Fibrillation in Primary Care Jeannie Hayhurst, CSNLC
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationCosting statement: Atrial fibrillation and heart valve disease: selfmonitoring coagulation status using point-of-care coagulometers (the CoaguChek XS)
Putting NICE guidance into practice Costing statement: Atrial fibrillation and heart valve disease: selfmonitoring coagulation status using point-of-care coagulometers (the CoaguChek XS) Published: September
More informationAsymptomatic Atrial Fibrillation: Detection and Management. 18 December nd Annual Advances in Heart Disease Palace Hotel, San Francisco
Asymptomatic Atrial Fibrillation: Detection and Management 18 December 2015 32 nd Annual Advances in Heart Disease Palace Hotel, San Francisco Zian H. Tseng, M.D., M.A.S. Associate Professor of Medicine
More informationAlison Tennant MRPharmS MPH Head of Service Improvement and Quality Dudley CCG
Alison Tennant MRPharmS MPH Head of Service Improvement and Quality Dudley CCG Commissioning is the set of linked activities required to assess the healthcare needs of a population, specify the services
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationThe Galway Experience
The Galway Experience Dr. Ruairi Waters 14.09.2018 Main acute hospital in West of Ireland Model 4 Hospital with 24/7 care Teaching Hospital (NUIG) Supra regional centre for cancer and cardiac services
More informationControversies in Atrial Fibrillation and HF
Controversies in Atrial Fibrillation and HF Dr.Yahya Al Hebaishi Cardiac electrophysiology division, PSCC, Riyadh Atrial Fibrillation: Rate or Rhythm? HF and AF: the twin epidemic of cardiovascular disease.
More informationIntegrated Diabetes Care in Oxfordshire -patient's perspective. Avril Surridge
Integrated Diabetes Care in Oxfordshire -patient's perspective Avril Surridge Today How does diabetes care in Oxfordshire look like from a patient s perspective? Good things What could be improved? National
More informationShow Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationA Guide to AF within the Cardiovascular Disease Outcomes Strategy
A Guide to AF within the Cardiovascular Disease Outcomes Strategy Registered Charity No. 1122442 1 Foreword Through my experience as a Member of Parliament, Chair of the All-Party Parliamentary Group on
More informationAtrial Fibrillation Collaborative. Thursday 7 May 2015
Atrial Fibrillation Collaborative Thursday 7 May 2015 Welcome and introductions Peter Carpenter KSS AHSN Nicky Jonas SEC CVD SCN AF Project Support KSS Academic Health Science Network & South East Cardiovascular
More informationNorth Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease
Guidelines on oral antiplatelet therapy in cardiovascular disease This guidance should be considered as one part of the wider therapeutic management of patients. The indication for antiplatelet therapy
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationWeighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated?
Weighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated? Albert L. Waldo, MD, PhD (Hon) The Walter H. Pritchard Professor of Cardiology, Professor of Medicine,and
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationSouth Norfolk CCG Dementia Strategy and Action Plan Dr Tony Palframan, SNCCG Governing Body Member
Agenda item: 9.4 Subject: Presented by: Submitted to: South Norfolk CCG Dementia Strategy and Action Plan Dr Tony Palframan, SNCCG Governing Body Member Governing Body Date: 28 th July Purpose of paper:
More informationPage 1. Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion. Atrial fibrillation: Scope of the problem
Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion Benjamin A. D Souza, MD, FACC, FHRS Assistant Professor of Clinical Medicine Penn Presbyterian Medical Center Cardiac
More informationSUPPLEMENTAL MATERIALS
SUPPLEMENTAL MATERIALS Table S1: Variables included in the propensity-score matching Table S1.1: Components of the CHA 2DS 2Vasc score Table S2: Crude event rates in the compared AF patient cohorts Table
More informationDr Mammen Ninan GPwSI in Cardiology
Dr Mammen Ninan GPwSI in Cardiology AF affects up to 835,000 people in England alone and is expected to rise year after year. AF is a known risk factor for stroke, the 3 rd highest cause of mortality in
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationA New Approach to Addressing the Heart Failure Challenge in Primary Care within the Western Locality of NEW DEVON CCG
A New Approach to Addressing the Heart Failure Challenge in Primary Care within the Western Locality of NEW DEVON CCG Dr Rosie Heath GP Principal Church view medical centre and GPwSI Western locality Cardiology
More informationwww.stopastroke.co.uk Acknowledgements Rachel Rayment Graham Shortland Tristan Groves Sarah Holroyd Shakeel Ahmad Steve Gage Darrell Baker Fiona Walker Clare Evans Marilyn Rees Kay Jeynes Peter O Callaghan
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Clinical guideline for the management of atrial fibrillation
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Clinical guideline for the management of atrial fibrillation 1.1 Short title Atrial fibrillation 2 Background a) The National Institute
More informationFour Years of NHS Health Checks in Barnsley - Outcomes and Inequalities
Four Years of NHS Health Checks in Barnsley - Outcomes and Inequalities Summary After four years of NHS Health Checks, Barnsley has access to aggregated data on over 47,000 people. This data was analysed
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationMedicines Management Team Update
Medicines Management Team Update Medicines Optimisation in 2017 Deprescribing/reducing variation Care homes Dietetics Improving Clinical outcomes e.g. reducing stroke, Antibiotics Joint Formulary Responses
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
More informationMonitoring Protocol for Clozapine-induced Myocarditis. Copyright 2017, CAMH
1 Monitoring Protocol for Clozapine-induced Myocarditis 1 Agenda Problem Identification / Identification Importance / Importance Baseline Workflow Baseline Workflow Baseline Data Baseline Data Objectives
More informationCosting report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)
Putting NICE guidance into practice Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181) Published: July 2014 This costing report accompanies Lipid modification:
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationAtrial fibrillation: current approaches to management
DRUG REVIEW n Atrial fibrillation: current approaches to management Upasana Tayal MA, MRCP and Robert Greenbaum BSc, MD, FRCP, FESC, FACC Atrial fibrillation is the commonest arrhythmia and GPs have an
More informationState of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data
State of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data Massimo Grimaldi Ospedale F. Miulli Acquaviva delle Fonti - Bari Disclosure Biosense
More informationstroke.org.uk Atrial Fibrillation Reducing your risk of stroke
stroke.org.uk Atrial Fibrillation Reducing your risk of stroke What is AF? Atrial Fibrillation (AF) is the most common type of irregular heartbeat. Over 1 million people in the UK are living with the condition,
More informationPRESENTATION TITLE. Case Studies
PRESENTATION TITLE Case Studies 1) SH is a 67 year old male. He has a history of type 2 diabetes, controlled hypertension and peripheral artery disease. He takes naproxen 500mg bd for arthritis and admits
More informationIMPACT-AFib: An 80,000 Person Randomized Trial Using the FDA Sentinel System Platform
IMPACT-AFib: An 80,000 Person Randomized Trial Using the FDA Sentinel System Platform January 5, 2018 NIH Collaboratory Grand Rounds Christopher Granger, MD Sean Pokorney, MD Duke Clinical Research Institute
More informationGOVERNING BODY MEETING in Public 22 February 2017 Agenda Item 3.4
GOVERNING BODY MEETING in Public 22 February 2017 Paper Title Purpose of paper Redesign of Services for Frail Older People in Eastern Cheshire To seek approval from Governing Body for the redesign of services
More information2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation
European Heart Journal 2012 doi:10.1093/eurheartj/ehs253 ESC 2012 2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation An update of the 2010 ESC Guidelines for the Management
More informationStudy period Total sample size (% women) 899 (37.7%) Warfarin Aspirin
Table S2 Sex- specific differences in oral anticoagulant prescription for stroke prevention in AF Total sample size (% women) Anticoagulant(s) studied Gage (2000) 1 Missouri, USA Discharged during 597
More informationModern aspects in multidisciplinary thromboembolic prophylaxis. AMPLATZER Left Atrial Appendage data update
Modern aspects in multidisciplinary thromboembolic prophylaxis AMPLATZER Left Atrial Appendage data update Igal Moarof, MD Interventional Cardiology Kantonsspital Aarau Potential conflicts of interest
More informationAF Diagnosis. Incorporated into over 75 health checks and Public Health Checks
AF Diagnosis Incpated into over 75 health checks and Public Health Checks Pulse Feel the pulse in all >65yrs If irregular do a 12 Lead ECG with Rhythm strip Check Thyroid and FBC and heart rate Refer to
More informationControversies in Risk Stratification
Controversies in Risk Stratification Things are not as simple as they seem Banff 2017 2015 MFMER 3494750-5 Relative importance Triggers vs Substrate in Pathophysiology of AF AF burden Paroxysmal? Persistent?
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationKnowsley Community. Stroke Team.
Knowsley Community Stroke Team julia.owens@lhch.nhs.uk marie.florian@lhch.nhs.uk 0151 244 3369 Knowsley Cardiovascular Disease Service Community Cardiovascular Service Rehabilitation services One stop
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital
More informationΑΣΥΜΠΤΩΜΑΤΙΚΗ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ
ΑΣΥΜΠΤΩΜΑΤΙΚΗ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΓΕΩΡΓΙΟΣ ΣΤΑΥΡΟΠΟΥΛΟΣ Β ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΠΓΝΘ ΙΠΠΟΚΡΑΤΕΙΟ 9 Ο Βορειοελλα ATRIAL FIBRILATION Atrial fibrillation (AF) is the most common clinically significant heart
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationSpontaneous Atrial Fibrillation and Noacs and Reversal agents
Spontaneous Atrial Fibrillation and Noacs and Reversal agents Laurent Lewkowiez, MD Regional Service Chief, Hospital Cardiology CPMG Cardiac Electrophysiology Educational Goals relationship between atrial
More informationLeft Atrial Appendage Closure Devices. Atrial Fibrillation 10/11/2017
Left Atrial Appendage Closure Devices Emile Daoud, MD Chief, Cardiac Electrophysiology Wexner Medical Center, The Ohio State University Atrial Fibrillation 1 Adjusted Annual Stroke Risk Using CHA 2 DS
More informationManagement of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39
Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationShaping Diabetes Services in Southern Derbyshire. A vision for Diabetes Services For Southern Derbyshire CCG
Shaping Diabetes Services in Southern Derbyshire A vision for Diabetes Services For Southern Derbyshire CCG Vanessa Vale Commissioning Manager September 2013 Contents 1. Introduction 3 2. National Guidance
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationECG monitoring after ischemic stroke of TIA of unknown source with an insertable monitor? YES
ECG monitoring after ischemic stroke of TIA of unknown source with an insertable monitor? YES Isabelle C Van Gelder University Medical Center Groningen The Netherlands ESC stroke council Prague January
More informationStroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital
Stroke secondary prevention Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke recurrence The risk of recurrent stroke is greatest after first stroke 2 3% of survivors of a first stroke
More informationNational Medicines Management Programme
National Medicines Management Programme Michael Barry 28 th November 2013 The Medicines Management Programme Multi-disciplinary Medicines Management Programme (MMP) headed by the National Medicines Information
More informationWhat evidence is there that variable clinical responses to PK parameters exist for NOACs? What conclusions can we draw from these data?
Is There A Role For Pharmacokinetic/Pharmacodynamics Guided Dosing For Novel Anticoagulants? The Heart House, Washington, DC, 3 December 2015 What evidence is there that variable clinical responses to
More information